文献速递艾滋病与性传播感染

基因型敏感度评分与病毒抑制HIV-1患者CD4恢复的关系

Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load.
PubMed 文献 · J Antimicrob Chemother · 2016-12-20

调整混杂因素后,GSS仅在换药至病毒抑制期间与CD4恢复呈边缘关联(P=0.06),病毒再抑制后GSS对后续CD4恢复无显著影响。

要点

  • 换药至病毒抑制期间,GSS较高者CD4恢复有边缘趋势(P=0.06)。
  • 病毒再抑制后,新方案GSS对后续CD4恢复无进一步影响。
  • 换药时CD4计数和血浆病毒载量是CD4恢复的主要相关因素。

核心结论

  • 病毒再抑制后,新方案GSS对后续CD4恢复无进一步影响。

主要发现

  • 未调整分析中,较高GSS与换药至1年期间更大的CD4恢复相关(P=0.010)。
  • 调整换药前临床和人口学变量后,GSS效应不再有统计学意义。
  • 仅较低的换药前CD4计数与抑制后1年内CD4恢复增加相关,未调整和调整模型均一致。
  • 主要CD4恢复发生在换药至病毒抑制期间,相关变量为换药时CD4和血浆病毒载量,GSS呈边缘趋势(P=0.06)。

临床怎么用

  • 换药时应优先考虑实现病毒抑制,GSS对后续CD4恢复的预测价值有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: HIV drug resistance, measured by the genotypic susceptibility score (GSS), has a deleterious effect on the virological outcome of HIV-1-infected patients. However, it is not known if GSS retains any predictive value for CD4 recovery in patients with suppressed viral load. METHODS: Four hundred and six patients on virological failure (>500 copies/mL) with GSS : <6 months prior to switch therapy who achieved undetectable plasma viral load (<50 copies/mL) within 1 year, remained undetectable >1 year on an unchanged regimen and had CD4 data available during entire follow-up were included. Adjusted and unadjusted analyses of all characteristics at switch related to CD4 recovery were made for three time frames: (i) 'switch-suppression'; (ii) 'suppression-1 year'; and (iii) 'switch-1 year'. RESULTS: Higher GSS was associated with a greater CD4 recovery between 'switch' and '1 year' in the unadjusted analysis (P = 0.010); however, the effect of GSS was no longer statistically significant after adjusting for pre-switch clinical (CD4 count and plasma viral load) and demographic variables. Furthermore, only a lower pre-switch CD4 count was associated with increased CD4 recovery in the 'suppression-1 year' period in both unadjusted and adjusted models. The main CD4 recovery occurred in 'switch-suppression' and the variables associated, both unadjusted and adjusted, were CD4 and plasma viral load at switch, maintaining a trend for GSS (P = 0.06). CONCLUSIONS: In individuals who re-suppressed HIV viraemia after switching therapy, regimens having a higher GSS were associated with improved CD4 recovery only during the period from switch to virological suppression, but, once viral load is re-suppressed, the GSS of the new regimen has no further effect on subsequent CD4 recovery.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gonzalez-Serna A, Glas AC, Brumme CJ, et al. Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load. J Antimicrob Chemother. 2016. PMID: 27999069. doi:10.1093/jac/dkw455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。